Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, 2-period, 2-treatment, 2-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of 2 Oral Preparations in Tablets With 1g of Cephalexin (Keflex® Made in Mexico by Eli Lilly vs. Keflex® Made in Italy by Facta) in Fasting Healthy Participants

NCT02100826 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02100826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02100826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, 2-period, 2-treatment, 2-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of 2 Oral Preparations in Tablets With 1g of Cephalexin (Keflex® Made in Mexico by Eli Lilly vs. Keflex® Made in Italy by Facta) in Fasting Healthy Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2014
Completion date
May 31, 2014
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers